Accelerated development of malaria monoclonal antibodies

Narimane Nekkab, Melissa A. Penny

Research output: Contribution to journalComment/debatepeer-review


L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 These promising results are the first of many to usher in a potential new era of malaria prevention.

Original languageEnglish
Article number100786
JournalCell Reports Medicine
Issue number10
Publication statusPublished - 18 Oct 2022


Dive into the research topics of 'Accelerated development of malaria monoclonal antibodies'. Together they form a unique fingerprint.

Cite this